Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 3,189 shares at $250.21 ($803K) on 2025-02-18, disclosed to the SEC on 2025-02-18.
Scheduled sale ($803k) by CSO & EVP, Head of Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $252.50 | 145 | $37K | 4.6% |
| 2 | $253.37 | 164 | $42K | 5.2% |
| 3 | $254.35 | 110 | $28K | 3.5% |
| 4 | $255.56 | 47 | $12K | 1.5% |
| 5 | $256.29 | 53 | $14K | 1.7% |
| 6 | $257.51 | 26 |
| $7K |
| 0.8% |
| 7 | $258.07 | 33 | $9K | 1.1% |
| 8 | $259.72 | 12 | $3K | 0.4% |
| 9 | $260.57 | 21 | $5K | 0.7% |
| 10 | $261.45 | 26 | $7K | 0.8% |
| 11 | $263.33 | 12 | $3K | 0.4% |
| 12 | $264.87 | 14 | $4K | 0.5% |
| 13 | $250.21 | 1,086 | $272K | 33.8% |
| 14 | $250.21 | 1,086 | $272K | 33.8% |
| 15 | $251.60 | 115 | $29K | 3.6% |
| 16 | $256.05 | 80 | $20K | 2.6% |
| 17 | $257.79 | 76 | $20K | 2.4% |
| 18 | $259.10 | 83 | $22K | 2.7% |
| Total | $251.86 avg | 3,189 | $803K | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $1.3M | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.4M | — | Filing → |
| ALNY | SELL | 2025-11-19 | $7.1M | — | Filing → |